BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xue M, Zeng Y, Qu HQ, Zhang T, Li N, Huang H, Zheng P, Hu H, Zhou L, Duan Z, Zhang Y, Bao W, Tian LF, Hakonarson H, Zhong N, Zhang XD, Sun B. Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19. ERJ Open Res 2021;7:00741-2020. [PMID: 33564671 DOI: 10.1183/23120541.00741-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hessami A, Rezaei N. Cardiovascular diseases burden in COVID-19. Am J Emerg Med 2021:S0735-6757(21)00803-2. [PMID: 34627644 DOI: 10.1016/j.ajem.2021.09.066] [Reference Citation Analysis]
2 Wang P, Chi L, Zhang Z, Zhao H, Zhang F, Linhardt RJ. Heparin: An old drug for new clinical applications. Carbohydrate Polymers 2022. [DOI: 10.1016/j.carbpol.2022.119818] [Reference Citation Analysis]
3 Lee Y, Jehangir Q, Lin C, Li P, Sule AA, Poisson L, Balijepally V, Halabi AR, Patel K, Krishnamoorthy G, Nair GB. 3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. JCM 2022;11:3949. [DOI: 10.3390/jcm11143949] [Reference Citation Analysis]
4 Akın Şen İ, Karaşahin Ö, Şebin E, Şen C. Use of azurocidin (heparin binding protein) and interleukin-1ß as prognostic indicators in COVID-19 patients. Eur J Inflamm 2022;20:1721727X2211051. [DOI: 10.1177/1721727x221105129] [Reference Citation Analysis]